

Screening and determination of synthetic PDE-5 inhibitors in adulterated sexual enhancement supplements**Sabaa Al Hemyari**

Emirates Health Services, UAE

This paper reports an important investigation and quantification of adulteration of sexual enhancement supplements with prescription medicines available in United Arab Emirates (UAE): tadalafil, sildenafil and vardenafil. A total of 158 sexual enhancement supplements were collected and analyzed in the current study. The samples were screened using REVERSE-Phase Liquid Chromatography tandem high-resolution Mass Spectrometry/Mass Spectrometry (RP-HPLC-MS/MS). Of all sexual enhancements, 12.7% (95% CI: 7.4–18) contained undeclared sildenafil, 3.8% (95% CI: 0.78–6.81) contained undeclared tadalafil and 1.9% (95% CI: 0.25–4.05) contained undeclared vardenafil. Of all sexual enhancement supplements, 13.9% (95% CI: 8.5–19.4) contained significant concentrations of sildenafil, tadalafil or vardenafil. While the study found relatively low levels of undeclared pharmaceutical ingredients in the sexual enhancement dietary supplements available on the UAE market, it is likely that patients with ED tend to consume multiple such supplements daily, thereby exposing themselves to highly elevated cumulative levels.

Biography

Sabaa Alhemyari has completed her MSc in clinical pharmacy from AUST, UAE and is a PhD candidate (JUNE 2023), Malaysia, USM. She is a member at Pharmacy department, EHS. She has published more than 36 papers in reputed journals.

Received: February 07, 2023; **Accepted:** February 10, 2023; **Published:** February 23, 2023